94 results on '"Skov M"'
Search Results
2. Intraspinal pressure is not elevated after traumatic spinal cord injury in a porcine model sham-controlled trial
3. A traumatic spinal cord injury critical care porcine model
4. Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to-patient contact
5. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis
6. P374 Effect of CFTR-modulators on cystic fibrosis related school absenteeism in children attending primary school.
7. 33 Risk factors for chronic colonization with Aspergillus fumigatus in people with cystic fibrosis
8. P110 Change in sweat chloride concentration after elexacaftor/tezacaftor/ivacaftor initiation: results from 12 months follow-up in the Danish cystic fibrosis cohort
9. EPS6.03 Pulmonary pathogen prevalence 12 months after elexacaftor/tezacaftor/ivacaftor introduction: results from the Danish National Cystic Fibrosis Cohort
10. EPS1.04 Change in lung clearance index in adolescents with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: results from 12 months follow-up in the Danish cystic fibrosis cohort
11. WS18.04 Change in markers of systemic inflammation after elexacaftor/tezacaftor/ivacaftor initiation: results from 18 months follow-up in the Danish cystic fibrosis cohort
12. WS12.01 Early growth in Danish children with cystic fibrosis since 2000
13. WS08.02 Change in hepatobiliary ultrasound measures, incl. shear wave elastography, after introduction of elexacaftor/tezacaftor/ivacaftor: results from 12-month follow-up in the Danish cystic fibrosis cohort
14. WS01.04 Longtime follow-up on exercise capacity and quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/iIvacaftor – a Copenhagen cohort
15. Immunoglobulin allotypes and IgG subclass antibody response to Aspergillus fumigatus in cystic fibrosis patients
16. WS19.01 Prospective measurement of lung function in 0–4-year-old Danish children with cystic fibrosis
17. P132 Reduced systemic immune responses in cystic fibrosis patients
18. P123 Features of the immune response to Mycobacterium abscessus complex (MABSC) and the influence of BCG vaccination
19. P108 Cross-sectional and longitudinal comparison of N2 and SF6 multiple breath washout in children with cystic fibrosis aged 2–45 months
20. P103 Longitudinal SF6 multiple breath washout testing in children aged 0–4 years with cystic fibrosis
21. Core genome multi-locus sequence typing as an essential tool in a high-cost livestock-associated meticillin-resistant Staphylococcus aureus CC398 hospital outbreak.
22. P275 Impact of administration mode of Pancreatic Enzyme Replacement Therapy (PERT) on abdominal pain, bowel habits and Quality of Life (QoL) in children and adolescents with cystic fibrosis: a randomised cross-over intervention study
23. WS06.6 Longitudinal SF6 Multiple Breath Washout measurements in infants and young children with cystic fibrosis born after implementation of newborn screening
24. WS08.5 Omics-based surveillance of Pseudomonas aeruginosa infection identifies clonal persistence despite ‘eradication’
25. P283 Impact of administration mode of Pancreatic Enzyme Replacement Therapy (PERT) on abdominal pain, bowel habits and quality of life (QoL) in children and adolescents with cystic fibrosis - a randomised cross-over intervention study: preliminary data
26. P189 Feasibility of multiple breath washout in a clinical setting in infants with cystic fibrosis
27. P186 Impact of bronchoalveolar lavage and related treatment on clinical outcomes in children with cystic fibrosis based on increases in the Lung Clearance Index
28. WS11-2 Trabecular bone score is associated with lean mass index in cystic fibrosis
29. WS02-2 Cardio-Pulmonary Exercise Test (CPET) is feasible in young children with cystic fibrosis aged six to twelve years and may be a valuable monitoring tool
30. P236 Life coaching among young adults with cystic fibrosis - a qualitative study
31. P044 Azithromycin resistance develops fast in P. aeruginosa but has no negative impact on lung function development in CF patients with chronic infection
32. WS19.3 Does lung clearance index (LCI) reflect levels of IL-8 and IL-1β in BAL fluids from children with stable CF pulmonary disease?
33. WS05.5 Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis
34. 76 Sinus surgery postpones chronic Gram-negative lung infection: cohort study of 106 patients with cystic fibrosis
35. 80 Persistence of Pseudomonas aeruginosa in early stages of airway infection
36. WS17.2 Comparison of FibroScan and Real-Time Elastography (RTE) to conventional ultrasound in the diagnosis of cystic fibrosis related liver disease (CFLD) in children and young adults at the Copenhagen CF-Center: a cross-sectional study
37. WS11.5 The consequences of no newborn cystic fibrosis screening in a well-developed country
38. 52 Specific Pseudomonas aeruginosa IgG levels before and after elexacaftor/tezacaftor/ivacaftor treatment.
39. 155 Aspergillus pulmonary infections in children with cystic fibrosis (CF): prevalences in three Scandinavian CF centres
40. WS20.3 Lung clearance index and Aspergillus colonization are clinical markers of chronic lung changes by spirometry controlled CT in children with cystic fibrosis
41. WS14.1 Day-time variability and short term effect of chest physiotherapy on multiple breath nitrogen washout in children with cystic fibrosis
42. 92 Early treatment with inhaled antibiotics postpones recurrence of Achromobacter species in cystic fibrosis
43. P002: Growth, lung microbiology and structure after implementation of newborn screening in Danish cystic fibrosis patients.
44. 353 Achromobacter xylosoxidans in cystic fibrosis: indirect patient-to-patient contact can lead to cross-infection
45. WS24.2 Extensive sinus surgery and follow-up can eradicate pathogenic bacterial sinusitis in patients with cystic fibrosis (CF)
46. WS1.3 Prevalence of cystic fibrosis related diabetes unaffected by steadily improving clinical condition. A Danish retrospective birth cohort
47. The paranasal sinuses are focus for colonisation and chronic biofilm lung infection in CF patients
48. 200 Clinical usefulness of bronchoalveolar lavage (BAL) of patients with Cystic Fibrosis
49. 121. Genetic factors and association of CF and ABPA
50. 643 Effect of elexacaftor/tezacaftor/ivacaftor treatment on fat-soluble vitamin plasma concentrations in children and adolescents with cystic fibrosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.